pd168393 has been researched along with bibw 2992 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barf, T; Kaptein, A | 1 |
| Chen, TH; Fischer, F; Getlik, M; Greulich, H; Heuckmann, JM; Heynck, S; Klüter, S; Koker, M; Pawar, VG; Peifer, M; Rabiller, M; Rauh, D; Reuter, C; Rode, HB; Ruddigkeit, L; Simard, JR; Sos, ML; Thomas, RK; Weiss, J; Yuza, Y | 1 |
1 review(s) available for pd168393 and bibw 2992
| Article | Year |
|---|---|
Irreversible protein kinase inhibitors: balancing the benefits and risks.
Topics: Animals; Cell Line; Humans; Protein Kinase Inhibitors; Protein Kinases; Risk; Structure-Activity Relationship; Time Factors | 2012 |
1 other study(ies) available for pd168393 and bibw 2992
| Article | Year |
|---|---|
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
Topics: Afatinib; Amino Acid Substitution; Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Furans; Humans; Lung Neoplasms; Molecular Structure; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2010 |